Home > News > Ministry stays DGGI ban on Natco's generic cancer drug
January 11th, 2010
Ministry stays DGGI ban on Natco's generic cancer drug
Abstract:
Natco Pharma today said the government has stayed an order of the Drug Controller-General of India (DCGI) which had stopped the company from producing breast cancer drug Albupax after it failed a toxicity test.
"The government of India has stayed the suspension of Albupax manufacturing (product) licence. Natco would announce its future plans shortly," the pharma firm said in a filing to the BSE.
Albupax, a nanotechnology-based drug, is the first generic version of abraxane, originally manufactured originally by US-based Abraxis Bioscience. Abraxis had complained about the side effects of Natco's version of the medicine.
Source:
domain-b.com
Bookmark:
| Related News Press |
News and information
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Govt.-Legislation/Regulation/Funding/Policy
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Quantum engineers ‘squeeze’ laser frequency combs to make more sensitive gas sensors January 17th, 2025
Chainmail-like material could be the future of armor: First 2D mechanically interlocked polymer exhibits exceptional flexibility and strength January 17th, 2025
Nanomedicine
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Nanobiotechnology
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Next-generation drug delivery innovation! DGIST develops precision therapeutics using exosomes April 25th, 2025
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||